Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...

Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.

Biosimilars sales were $201.5 million, up 7% driven by Benepali, with sales of $125 million, up 16%. LEQEMBI global in-market sales in the quarter were approximately $87 million, including U.S.

Scotiabank lowered the firm’s price target on Biogen (BIIB) to $224 from $244 and keeps an Outperform rating on the shares. Fiscal year results ...

RBC Capital lowered the firm’s price target on Biogen (BIIB) to $225 from $231 but keeps an Outperform rating on the shares after its Q4 ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...